How are FibroTest (FT) and ActiTest (AT) used to assess liver fibrosis and necro‑inflammatory activity, and what do their scores indicate?

FibroTest and ActiTest: Non-Invasive Assessment Tools for Liver Disease

FibroTest (FT) and ActiTest (AT) are proprietary blood-based biomarker panels that provide quantitative estimates of liver fibrosis and necro-inflammatory activity, respectively, serving as validated alternatives to liver biopsy across multiple chronic liver diseases.

What These Tests Measure

FibroTest (Fibrosis Assessment)

• Purpose: Quantifies liver fibrosis stage as a continuous score from 0 to 1
• Components: Combines multiple serum biomarkers (α2-macroglobulin, haptoglobin, apolipoprotein A1, GGT, total bilirubin) adjusted for age and gender
• Diagnostic Performance: AUROC of 0.80-0.89 for detecting advanced fibrosis (≥F3) and cirrhosis (F4) 1, 2
• Interpretation:
  • FT <0.27 = minimal/no fibrosis (F0-F1)
  • FT 0.27-0.48 = intermediate zone
  • FT >0.48 = significant fibrosis (≥F2)
  • Higher cutoffs indicate advanced fibrosis/cirrhosis

ActiTest (Inflammatory Activity Assessment)

• Purpose: Grades necro-inflammatory activity in the liver
• Diagnostic Performance: AUROC of 0.80-0.83 for detecting moderate-to-severe inflammatory activity 3, 4
• Interpretation:
  • AT ≤0.29 = minimal activity (A0-A1)
  • AT 0.29-0.50 = intermediate
  • AT >0.50 = moderate-to-severe activity (≥A2)

Clinical Applications and Performance

Validated Disease Contexts

FibroTest and ActiTest perform best in:

• Chronic hepatitis C (most extensively validated) 1, 5
• Chronic hepatitis B 6, 7, 8
• Alcoholic liver disease 9
• NAFLD/NASH 2, 3
• Autoimmune hepatitis 4, 10

Comparative Performance

FibroTest does not significantly outperform simpler non-patented scores like FIB-4 or NAFLD Fibrosis Score for detecting advanced fibrosis 2. However, it offers advantages:

• Provides continuous quantitative assessment across all fibrosis stages
• Can detect intermediate fibrosis stages better than binary cutoff scores 3
• Useful for longitudinal monitoring of disease progression or treatment response 2, 8

Important Limitations

Critical caveats to recognize:

1. Cost and Availability: These are proprietary tests requiring commercial laboratory processing, limiting widespread use compared to free calculators like FIB-4 2

2. Performance in Specific Populations:

   • Underperforms in patients with type 2 diabetes mellitus (AUROC 0.67-0.73) 11
   • Results should not be extrapolated from non-diabetic validation studies to diabetic populations

3. Cannot Replace Biopsy for:

   • Initial diagnosis requiring histological confirmation
   • Discordant results between multiple non-invasive tests
   • Assessment of other histological features (steatosis grade, ballooning, specific inflammatory patterns)

4. Positive Predictive Value: Modest PPV (<70%) means elevated scores require confirmation with additional testing or biopsy 12

Practical Clinical Algorithm

When to use FibroTest/ActiTest:

1. As secondary assessment after initial screening with FIB-4 or NFS shows intermediate results (FIB-4 1.3-2.67) 13, 12

2. For serial monitoring in patients with established chronic liver disease to track:

   • Fibrosis progression/regression over time
   • Response to antiviral therapy 8
   • Response to lifestyle interventions

3. When elastography unavailable or technically unreliable (obesity, ascites) 2

4. Combined interpretation: Use alongside transient elastography for improved diagnostic accuracy—the combination performs better than either alone 1, 14

When NOT to rely solely on these tests:

• Patients requiring definitive NASH diagnosis (biopsy remains necessary) 14, 2
• Diabetic patients (consider alternative validated tools) 11
• When results conflict with clinical presentation or other non-invasive tests 13

Prognostic Value

Both FibroTest and ActiTest predict clinical outcomes beyond just histological correlation 6, 7:

• 5-year overall survival in chronic hepatitis B (FT hazard ratio superior to viral load)
• Liver-related mortality and complications
• Risk stratification for hepatocellular carcinoma surveillance
• Need for variceal screening in advanced fibrosis 2

The combination of FibroTest-ActiTest with viral load provides 100% negative predictive value for identifying true inactive carriers in hepatitis B 7, demonstrating clinical utility beyond simple fibrosis staging.